Lindbrook Capital’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-142
| Closed | – | – | 2956 |
|
|
2024
Q3 | $0 | Hold |
142
| – | – | ﹤0.01% | 2950 |
|
|
2024
Q2 | $6.1K | Hold |
142
| – | – | ﹤0.01% | 1893 |
|
|
2024
Q1 | $6.01K | Hold |
142
| – | – | ﹤0.01% | 1815 |
|
|
2023
Q4 | $5.93K | Buy |
142
+104
| +274% | +$3.83K | ﹤0.01% | 1795 |
|
|
2023
Q3 | $1.43K | Hold |
38
| – | – | ﹤0.01% | 2239 |
|
|
2023
Q2 | $1.44K | Sell |
38
-75
| -66% | -$2.35K | ﹤0.01% | 2281 |
|
|
2023
Q1 | $2.75K | Sell |
113
-130
| -53% | -$3.79K | ﹤0.01% | 2107 |
|
|
2022
Q4 | $7.06K | Buy |
243
+62
| +34% | +$1.84K | ﹤0.01% | 1614 |
|
|
2022
Q3 | $5K | Buy |
181
+117
| +183% | +$4.03K | ﹤0.01% | 1709 |
|
|
2022
Q2 | $2K | Buy |
64
+20
| +45% | +$762 | ﹤0.01% | 2094 |
|
|
2022
Q1 | $2K | Sell |
44
-462
| -91% | -$21.6K | ﹤0.01% | 2122 |
|
|
2021
Q4 | $25K | Sell |
506
-122
| -19% | -$6.83K | ﹤0.01% | 952 |
|
|
2021
Q3 | $40K | Sell |
628
-20
| -3% | -$1.38K | 0.01% | 511 |
|
|
2021
Q2 | $47K | Buy |
648
+5
| +0.8% | +$367 | 0.01% | 497 |
|
|
2021
Q1 | $47K | Hold |
643
| – | – | 0.01% | 472 |
|
|
2020
Q4 | $47K | Buy |
643
+522
| +431% | +$33.6K | 0.01% | 423 |
|
|
2020
Q3 | $7K | Sell |
121
-43
| -26% | -$2.68K | ﹤0.01% | 991 |
|
|
2020
Q2 | $11K | Sell |
164
-145
| -47% | -$9.72K | ﹤0.01% | 818 |
|
|
2020
Q1 | $19K | Buy |
309
+289
| +1,445% | +$21.4K | 0.01% | 565 |
|
|
2019
Q4 | $2K | Hold |
20
| – | – | ﹤0.01% | 1332 |
|
|
2019
Q3 | $2K | Buy |
+20
| New | +$1.62K | ﹤0.01% | 1312 |
|
Other funds holding TARO
Lindbrook Capital's TARO Position: Q4 2024 in Review
Lindbrook Capital sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q4 2024, closing a stake of 142 shares.
Lindbrook Capital first reported a position in TARO in Q3 2019 and held it in 21 quarters. The position peaked at $47K in Q2 2021. 3 funds tracked by Wall St. Rank hold TARO as of Q4 2024.
- Lindbrook Capital reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q4 2024 after selling out during the quarter.
- Lindbrook Capital sold 142 Taro Pharmaceutical Industries Ltd. shares in Q4 2024.
- Lindbrook Capital first reported a position in Taro Pharmaceutical Industries Ltd. in Q3 2019 and held it in 21 quarters.
- Lindbrook Capital's Taro Pharmaceutical Industries Ltd. position peaked at $47K in Q2 2021.
- 3 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q4 2024.
Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.